Interaction of Human NAD(P)H:Quinone Oxidoreductase 1 (NQO1) with the Tumor Suppressor Protein p53 in Cells and Cell-free Systems*

NAD(P)H:quinone oxidoreductase 1 (NQO1) has been proposed to stabilize p53 via a redox mechanism involving oxidation of NAD(P)H as a consequence of the catalytic activity of NQO1. We report that treatment of HCT-116 human colon carcinoma cells with the NQO1 inhibitor ES936 had no effect on the levels of p53 protein. ES936 is a mechanism-based inhibitor of NQO1 that irreversibly blocks the catalytic function of the enzyme. This suggests that a redox mechanism involving NQO1-mediated NAD(P)H oxidation is not responsible for the stabilization of p53. We also examined the ability of the NQO1 protein to associate with p53 using co-immunoprecipitation experiments. Results from these experiments demonstrated co-immunoprecipitation of NQO1 with p53 and vice versa. The association between p53 and NQO1 was not affected by treatment of HCT-116 cells with ES936, demonstrating that the association was not dependent on the catalytic activity of NQO1. A comparison of isogenic HCT-116 p53+/+ and HCT-116 p53−/− cells demonstrated an interaction of NQO1 and p53 only in the p53+/+ cells. Experiments performed in an in vitrotranscription/translation system utilizing rabbit reticulocyte lysates confirmed the interaction of NQO1 and p53. In these experiments a full-length p53 coding region was used to express p53 in the presence of recombinant NQO1 protein. An association of p53 and NQO1 was also observed in primary human keratinocytes and mammary epithelial cells. In studies where mdm-2 co-immunoprecipitated with p53, no association of mdm-2 with NQO1 was observed. These data demonstrate an association between p53 and NQO1 that may represent an alternate mechanism of p53 stabilization by NQO1 in a wide variety of human cell types.

[1]  Yoichi Taya,et al.  Regulation of p53 activity by its interaction with homeodomain-interacting protein kinase-2 , 2002, Nature Cell Biology.

[2]  T. Naoe,et al.  Analysis of genetic polymorphism in NQO1, GST-M1, GST-T1, and CYP3A4 in 469 Japanese patients with therapy-related leukemia/ myelodysplastic syndrome and de novo acute myeloid leukemia. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[3]  L. Neckers,et al.  Stabilization of wild-type p53 by hypoxia-inducible factor 1α , 1998, Nature.

[4]  L. Amzel,et al.  Characterization of a mechanism-based inhibitor of NAD(P)H:quinone oxidoreductase 1 by biochemical, X-ray crystallographic, and mass spectrometric approaches. , 2001, Biochemistry.

[5]  D. Ross,et al.  Characterization of a polymorphism in NAD(P)H: quinone oxidoreductase (DT-diaphorase). , 1997, British Journal of Cancer.

[6]  K. Kinzler,et al.  Requirement for p53 and p21 to sustain G2 arrest after DNA damage. , 1998, Science.

[7]  D. Ross,et al.  DT-diaphorase in activation and detoxification of quinones , 1993, Cancer and Metastasis Reviews.

[8]  J. Lear,et al.  Association of NAD(P)H:quinone oxidoreductase (NQO1) null with numbers of basal cell carcinomas: use of a multivariate model to rank the relative importance of this polymorphism and those at other relevant loci. , 1999, Carcinogenesis.

[9]  D. Lane,et al.  The p53 tumour suppressor gene , 1998, The British journal of surgery.

[10]  D. Ross,et al.  Interaction of the Molecular Chaperone Hsp70 with Human NAD(P)H:Quinone Oxidoreductase 1* , 2002, The Journal of Biological Chemistry.

[11]  J. Pietenpol,et al.  Differential cell cycle checkpoint response in normal human keratinocytes and fibroblasts. , 1998, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[12]  L. Landi,et al.  The role of DT-diaphorase in the maintenance of the reduced antioxidant form of coenzyme Q in membrane systems. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[13]  K. Danenberg,et al.  NAD(P)H:quinone oxidoreductase gene expression in human colon carcinoma cells: characterization of a mutation which modulates DT-diaphorase activity and mitomycin sensitivity. , 1992, Cancer research.

[14]  T. Ebert,et al.  Increased frequency of a null-allele for NAD(P)H: quinone oxidoreductase in patients with urological malignancies. , 1997, Pharmacogenetics.

[15]  Prevalence of the inactivating 609C-->T polymorphism in the NAD(P)H:quinone oxidoreductase (NQO1) gene in patients with primary and therapy-related myeloid leukemia. , 1999 .

[16]  Z. Ronai,et al.  p53-Mdm2--the affair that never ends. , 2002, Carcinogenesis.

[17]  K. Vousden Activation of the p53 tumor suppressor protein. , 2002, Biochimica et biophysica acta.

[18]  J. Pietenpol,et al.  p53 Signaling and cell cycle checkpoints. , 2001, Chemical research in toxicology.

[19]  D. Ross,et al.  Rapid polyubiquitination and proteasomal degradation of a mutant form of NAD(P)H:quinone oxidoreductase 1. , 2001, Molecular pharmacology.

[20]  M. Oren,et al.  Mdm2 promotes the rapid degradation of p53 , 1997, Nature.

[21]  P. Talalay,et al.  Increase of NAD(P)H:quinone reductase by dietary antioxidants: possible role in protection against carcinogenesis and toxicity. , 1980, Proceedings of the National Academy of Sciences of the United States of America.

[22]  Lars Ernster [56] DT diaphorase , 1967 .

[23]  K. Tew,et al.  Glutathione S-transferase P1–1 (GSTP1–1) Inhibits c-Jun N-terminal Kinase (JNK1) Signaling through Interaction with the C Terminus* , 2001, The Journal of Biological Chemistry.

[24]  D. Ross,et al.  A note on the inhibition of DT-diaphorase by dicoumarol. , 1991, Free radical biology & medicine.

[25]  J. Milner,et al.  The interaction of p53 with the nuclear matrix is mediated by F-actin and modulated by DNA damage , 2002, Oncogene.

[26]  J. Heath,et al.  Hyaluronidase Induction of a WW Domain-containing Oxidoreductase That Enhances Tumor Necrosis Factor Cytotoxicity* , 2001, The Journal of Biological Chemistry.

[27]  O. H. Lowry,et al.  Protein measurement with the Folin phenol reagent. , 1951, The Journal of biological chemistry.

[28]  M. Pincus,et al.  Regulation of JNK signaling by GSTp , 1999, The EMBO journal.

[29]  D. Liebler,et al.  The Reduction of α-Tocopherolquinone by Human NAD(P)H:Quinone Oxidoreductase: The Role of α-Tocopherolhydroquinone as a Cellular Antioxidant , 1997 .

[30]  A. Levine,et al.  The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation , 1992, Cell.

[31]  H. Kawai,et al.  Dual Role of p300 in the Regulation of p53 Stability* , 2001, The Journal of Biological Chemistry.

[32]  S. Müller,et al.  Members of the PIAS family act as SUMO ligases for c-Jun and p53 and repress p53 activity , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[33]  J. Merchant,et al.  ZBP-89 Promotes Growth Arrest through Stabilization of p53 , 2001, Molecular and Cellular Biology.

[34]  F. Zindy,et al.  Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[35]  G. Morgan,et al.  Low NAD(P)H:quinone oxidoreductase 1 activity is associated with increased risk of acute leukemia in adults. , 2001, Blood.

[36]  M F Greaves,et al.  A lack of a functional NAD(P)H:quinone oxidoreductase allele is selectively associated with pediatric leukemias that have MLL fusions. United Kingdom Childhood Cancer Study Investigators. , 1999, Cancer research.

[37]  Ted R. Hupp,et al.  Strategies for manipulating the p53 pathway in the treatment of human cancer , 2000 .

[38]  D. Ross,et al.  Genotype-phenotype relationships in studies of a polymorphism in NAD(P)H:quinone oxidoreductase 1. , 1999, Pharmacogenetics.

[39]  K. Vousden,et al.  Stress Signals Utilize Multiple Pathways To Stabilize p53 , 2000, Molecular and Cellular Biology.

[40]  C. Huggins,et al.  INDUCED PROTECTION OF ADRENAL CORTEX AGAINST 7,12-DIMETHYLBENZ[a]ANTHRACENE , 1964, The Journal of Experimental Medicine.

[41]  D. Lane,et al.  Cancer: Awakening angels , 1998, Nature.

[42]  D. Ross,et al.  Metabolism of bioreductive antitumor compounds by purified rat and human DT-diaphorases. , 1994, Cancer research.

[43]  D. Labuda,et al.  Role of NQO1, MPO and CYP2E1 genetic polymorphisms in the susceptibility to childhood acute lymphoblastic leukemia , 2002, International journal of cancer.

[44]  K. Tew,et al.  Pharmacologic or genetic manipulation of glutathione S-transferase P1-1 (GSTpi) influences cell proliferation pathways. , 2001, The Journal of pharmacology and experimental therapeutics.

[45]  D. Roop,et al.  NAD(P)H:quinone oxidoreductase 1 deficiency increases susceptibility to benzo(a)pyrene-induced mouse skin carcinogenesis. , 2000, Cancer research.

[46]  M. Żylicz,et al.  Co‐chaperones Bag‐1, Hop and Hsp40 regulate Hsc70 and Hsp90 interactions with wild‐type or mutant p53 , 2001, The EMBO journal.

[47]  F. King,et al.  Hsp70 interactions with the p53 tumour suppressor protein , 2001, The EMBO journal.

[48]  L. Ernster,et al.  DT-diaphorase as a quinone reductase: a cellular control device against semiquinone and superoxide radical formation. , 1982, Archives of biochemistry and biophysics.

[49]  J. Lotem,et al.  NQO1 stabilizes p53 through a distinct pathway , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[50]  D. Roop,et al.  NAD(P)H:quinone oxidoreductase 1 deficiency and increased susceptibility to 7,12-dimethylbenz[a]-anthracene-induced carcinogenesis in mouse skin. , 2001, Journal of the National Cancer Institute.

[51]  S. Orrenius,et al.  The metabolism of menadione (2-methyl-1,4-naphthoquinone) by isolated hepatocytes. A study of the implications of oxidative stress in intact cells. , 1982, The Journal of biological chemistry.